THREAD Acquires Modus Outcomes
THREAD has acquired Modus Outcomes. Headquartered in Cambridge, Mass., Modus Outcomes is a research consultancy that supports the design and selection of electronic clinical outcome assessments (eCOA), participant-focused trial design and scientific delivery of DCTs.
With this acquisition, THREAD will bring together its eCOA technology platform with Modus' services. Modus brings to THREAD:
- Knowledge in qualitative research, advanced psychometric analysis and biostatistics
- Consulting capabilities specializing in patient-centered outcomes strategies, including instrument design/selection and regulatory support
- Outcomes researchers and company partners, Dr. Patrick Marquis, CEO, Dr. Stefan Cano, chief scientific officer, and Dr. Antoine Regnault, global lead, Statistics
- A team of 40 holding an array of certifications and specializations
- Offices in London and Lyon, France
Financial details of the acquisition are not being disclosed.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
